(Q38889516)

English

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Teresa Di Desidero

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

Christopher Jedeszko

1

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Marta Paez-Ribes

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Shan Man

4

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Christina R Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Ping Xu

6

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Georg A Bjarnason

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Guido Bocci

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Robert S Kerbel

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

0 references

publication date

1 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Science Translational Medicine

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

282

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

282ra50

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Treatment selection in metastatic renal cell carcinoma: expert consensus

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Targeting HIF-1 for cancer therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Resistance to targeted therapy in renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Practices and pitfalls of mouse cancer models in drug discovery.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Mouse models of advanced spontaneous metastasis for experimental therapeutics

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

What's wrong with our cancer models?

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Development of a preclinical model of spontaneous human melanoma central nervous system metastasis

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

In vivo selection of human renal cell carcinoma cells with high metastatic potential in nude mice

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Future directions in renal cell carcinoma: 2011 and beyond

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Drug combination studies and their synergy quantification using the Chou-Talalay method

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

In vitro cultivation of human renal cell cancer. II. Characterization of cell lines

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Tumour suppression by the human von Hippel-Lindau gene product

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010722

21 January 2018

Identifiers

10.1126/SCITRANSLMED.3010722

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38889516&oldid=1794068795"